<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940897</url>
  </required_header>
  <id_info>
    <org_study_id>KARMA2</org_study_id>
    <nct_id>NCT04940897</nct_id>
  </id_info>
  <brief_title>Use of Blood Ketone Meters to Improve Ambulance Hyperglycaemia Care</brief_title>
  <acronym>KARMA2</acronym>
  <official_title>Use of Capillary Blood Ketone Meters to Improve Ambulance Service Care of Hyperglycaemic Patients: a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East of England Ambulance Service NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>East of England Ambulance Service NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this KARMA2 feasibility study the investigators are testing whether ambulance staff can&#xD;
      reliably and safely identify patients at high risk of diabetic ketoacidosis using blood&#xD;
      ketone meters and start fluid (saline) therapy before arriving at hospital. The investigators&#xD;
      aim to include 800 patients in this stepped wedge control study and the results will help&#xD;
      decide if a larger study is warranted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic ketoacidosis (DKA) is a potentially life-threatening condition which requires&#xD;
      immediate treatment. National Health Service (NHS) hospital guidelines recommend immediate&#xD;
      fluid (saline) therapy. Delays in diagnosis and treatment are known to be associated with&#xD;
      health complications and death.&#xD;
&#xD;
      There is an opportunity to involve ambulance crews to improve DKA identification and&#xD;
      treatment times; however, currently ambulance staff do not have access to ketone testing, and&#xD;
      fluids are recommended only when it is thought a patient is critically unwell.&#xD;
&#xD;
      In this KARMA2 feasibility study the investigators are testing whether ambulance staff can&#xD;
      reliably and safely identify patients at high risk of DKA using blood ketone meters and start&#xD;
      fluid (saline) therapy before arriving at hospital.&#xD;
&#xD;
      During an 8-month period (4-month control followed by 4-month intervention), 120 ambulance&#xD;
      clinicians from the East of England Ambulance Service NHS Trust will receive training to&#xD;
      consent 400 patients with hyperglycaemia and unwell patients with diabetes to the control&#xD;
      group receiving usual care, followed by determining the presence of ketones using capillary&#xD;
      blood testing from a further 400 consenting patients with hyperglycaemia and unwell patients&#xD;
      with diabetes. Subsequent patient care will depend on the ketone value obtained: high-risk&#xD;
      DKA patients will receive fluid therapy.&#xD;
&#xD;
      Twenty ambulance and hospital clinicians will be invited to an online interview to share&#xD;
      views of DKA care and the impact of ambulance blood ketone meters. The results will help the&#xD;
      investigators decide if a larger study would be a good idea.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Stepped wedge control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure incidence of hyperglycaemia in study population</measure>
    <time_frame>18 months</time_frame>
    <description>Frequency count of capillary blood glucose level greater than 11mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure incidence of diabetic ketoacidosis (DKA) in study population</measure>
    <time_frame>18 months</time_frame>
    <description>Frequency count of capillary blood ketone level equal to or greater than 3mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Completeness of data capture by study clinicians</measure>
    <time_frame>18 months</time_frame>
    <description>Progression criteria requires full record completion for a minimum of 70 percent of participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure incidence of adverse events</measure>
    <time_frame>Maximum 18 months</time_frame>
    <description>Progression criteria requires adverse event rate to be less than 1 percent of participants</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">820</enrollment>
  <condition>Diabetic Ketoacidosis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Usual care plus ketone meter and fluid therapy for identified high risk DKA patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Use of CareSens ketone meter</intervention_name>
    <description>Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or more&#xD;
&#xD;
          -  Attended by study clinician&#xD;
&#xD;
          -  Informed or Proxy consent to participate&#xD;
&#xD;
          -  Blood glucose level greater than 11mmol/L or unwell with history of diabetes&#xD;
&#xD;
          -  If required will be transported to partner hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to meet inclusion criteria&#xD;
&#xD;
          -  Previously recruited to study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Davis</last_name>
    <role>Study Director</role>
    <affiliation>East of England Ambulance Service NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theresa Foster</last_name>
    <phone>+447971287986</phone>
    <email>theresa.foster@eastamb.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Larissa Prothero</last_name>
    <phone>+447736374453</phone>
    <email>larissa.prothero@eastamb.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>East of England Ambulance Service NHS Trust</name>
      <address>
        <city>Melbourn</city>
        <state>Cambs</state>
        <zip>SG8 6EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Foster</last_name>
      <phone>+447971287986</phone>
      <email>theresa.foster@eastamb.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Larissa Prothero</last_name>
      <phone>+447736374453</phone>
      <email>larissa.prothero@eastamb.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>East of England Ambulance Service NHS Trust</investigator_affiliation>
    <investigator_full_name>Theresa Foster</investigator_full_name>
    <investigator_title>Head of Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketosis</mesh_term>
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

